Chinese Academy Of Medical Sciences

SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Treatment with the novel antibody CM313 boosted platelet levels and demonstrated long-term durability among adults with immune thrombocytopenia, results from a phase 2 study showed.

Nearly 50% of patients with pretreated, locally advanced non-small cell lung cancer harboring a KRAS G12C mutation responded to treatment with glecirasib, findings from a phase 2 study conducted in China showed.

In a large cohort of Chinese women, preconception thyroid-stimulating hormone levels were linked to maternal outcomes, including preterm delivery, low birth weight and large for gestational age birth weight, according to study results.

The addition of toripalimab to first-line chemotherapy prolonged PFS and OS among patients with advanced non-small cell lung cancer without EGFR/ALK mutations, according to study results.

The addition of entinostat to exemestane improved PFS for patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to randomized phase 3 study results presented at San Antonio Breast Cancer Symposium.

Pyrotinib plus capecitabine prolonged OS and PFS compared with lapatinib-capecitabine among patients with pretreated HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Serum thyroglobulin levels after a lobectomy can be used to predict recurrence risk for adults with papillary thyroid carcinoma, according to findings published in Thyroid.